ACC 22: Results from the EMPULSE Study - Empagliflozin Proves Beneficial for Patients with HF

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

In this short interview, Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, Kansas City, MO, US) summarises the main findings of the EMPULSE STUDY, originally presented as a late-breaking trial at ACC 2022.
The results suggest that patients with acute heart failure (HF) benefit from the use of empagliflozin over 90 days when compared to a placebo. These findings were followed by marketing authorization for the use of empagliflozin in the US for the treatment of chronic HF (NCT04157751).

Discussion Points:
-Study Rationale
-Study Design and Patient Population
-Main Findings
-Recommendations for Use
-Take-home Messages
-Further Research Required

Recorded on-site in Washington DC, ACC Conference 2022.

Interviewer: Mirjam Boros
Editor: Jordan Rance

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.